176 results on '"Rottapel R"'
Search Results
2. Prevalence and morbidity of sleepiness among sleep apnea patients in an online cohort
- Author
-
Rottapel, R., primary, Reid, M., additional, Bertisch, S., additional, Bron, M., additional, Kapur, V.K., additional, Bujanover, S., additional, Harrington, Z., additional, Bakker, J.P., additional, Hanson, M., additional, Figetakis, K., additional, Page, K., additional, Hanes, S., additional, Villa, K.F., additional, and Redline, S., additional
- Published
- 2019
- Full Text
- View/download PDF
3. 1047 A Community-Based Sleep Health and Yoga Intervention to Improve Sleep Outcomes among Low-income and Racial/Ethnic Minority Adults
- Author
-
Spadola, C, primary, Zhou, E S, additional, Rottapel, R, additional, Gou, N, additional, Johnson, D A, additional, Weng, J, additional, Chen, J, additional, Redline, S, additional, and Bertisch, S M, additional
- Published
- 2018
- Full Text
- View/download PDF
4. suppressor of cytokine signaling-1 (Socs1) interacts with the M-CSF receptor and negatively regulates its proliferation signal
- Author
-
R.P., Bourette, Sepulveda P., De, Arnaud, S., Dubreuil, Pascal, Rottapel, R., Mouchiroud, G., and Laviron, Nathalie
- Subjects
[SDV.BC] Life Sciences [q-bio]/Cellular Biology - Published
- 2001
5. Effects of mant-tagged fluorescent nucleotides on small GTPase function: real-time NMR analysis of nucleotide hydrolysis and exchange kinetics
- Author
-
Mazhab-Jafari, M.T., Marshall, C.B., Smith, M., Seabrook, G., Stambolic, V., Rottapel, R., Neel, B.G., and Ikura, M.
- Subjects
DNA-ligand interactions -- Observations -- Usage ,Nuclear magnetic resonance -- Usage ,Hydrolysis -- Observations -- Usage ,Guanosine triphosphatase -- Properties -- Usage ,Biological sciences - Abstract
The Ras family of small GTPases control diverse signaling pathways through a conserved 'switch' mechanism, which is turned on by the binding of GTP and turned off by GTP hydrolysis. Full understanding of GTPase switch functions requires reliable, quantitative assays for nucleotide binding and hydrolysis. Fluorescently labeled guanine nucleotides, such as 2'(3')-O-(N-Methylanthraniloyl)-(mant)substituted GTP and GDP analogs, have been widely used to investigate the molecular properties of small GTPases, such as Ras, Rho, and Rab. Using a recently developed nuclear magnetic resonance method that can detect subtle conformational change of proteins, we show here how the kinetics of nucleotide hydrolysis and exchange by 3 small GTPases, alone and in the presence of their cognate GAPs and GEFs, are affected by the presence of the fluorescent mant moiety. Intrinsic hydrolysis of mantGTP by Rheb is much faster than that of GTP, whereas it is slower with RhoA. On the other hand, the mant tag inhibits TSC2 GAPcatalyzed GTP hydrolysis by Rheb, but promotes RasGAP334-catalyzed GTP hydrolysis by Ras. GEF catalyzed nucleotide exchange, by both Ras and RhoA, was inhibited by the presence of mant. These results indicate that the mant moiety can significantly affect GTPase reaction kinetics in an unpredictable manner, and underscore the importance of validating its use in each system., doi: 10.1139/O09-905 M.T. Mazhab-Jafari, C.B. Marshall, M. Smith, G. Seabrook, V. Stambolic, R. Rottapel, B.G. Neel, and M. Ikura Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, [...]
- Published
- 2010
- Full Text
- View/download PDF
6. 3BP2 deficient mice are osteoporotic with impaired osteoblast and osteoclast functions
- Author
-
Levaot, N., primary, Simoncic, P.D., additional, Dimitriou, I.D., additional, Scotter, A., additional, La Rose, J., additional, Willett, T.L., additional, Ng, A.H., additional, Wang, C.J., additional, Janmohamed, S., additional, Grynpas, M., additional, Reichenberger, E., additional, and Rottapel, R., additional
- Published
- 2011
- Full Text
- View/download PDF
7. [P1.21]: The Rho‐specific GEF IFC regulates neural precursor fate determination during cortical development
- Author
-
Gauthier‐Fisher, A., primary, Lin, D.C., additional, Greeve, M.A., additional, Rottapel, R., additional, Kaplan, D.R., additional, and Miller, F.D., additional
- Published
- 2008
- Full Text
- View/download PDF
8. Impaired V(D)J recombination and increased apoptosis among B cell precursors in the bone marrow of c-Abl-deficient mice
- Author
-
Lam, Q. L. K., primary, Lo, C. K. C., additional, Zheng, B.-J., additional, Ko, K.-H., additional, Osmond, D. G., additional, Wu, G. E., additional, Rottapel, R., additional, and Lu, L., additional
- Published
- 2007
- Full Text
- View/download PDF
9. The SH3 domain of Itk/Emt binds to proline-rich sequences in the cytoplasmic domain of the T cell costimulatory receptor CD28.
- Author
-
Marengère, L E, primary, Okkenhaug, K, additional, Clavreul, A, additional, Couez, D, additional, Gibson, S, additional, Mills, G B, additional, Mak, T W, additional, and Rottapel, R, additional
- Published
- 1997
- Full Text
- View/download PDF
10. The c-kit receptor ligand functions as a mast cell chemoattractant
- Author
-
Meininger, CJ, primary, Yano, H, additional, Rottapel, R, additional, Bernstein, A, additional, Zsebo, KM, additional, and Zetter, BR, additional
- Published
- 1992
- Full Text
- View/download PDF
11. The Steel/W transduction pathway: kit autophosphorylation and its association with a unique subset of cytoplasmic signaling proteins is induced by the Steel factor.
- Author
-
Rottapel, R, primary, Reedijk, M, additional, Williams, D E, additional, Lyman, S D, additional, Anderson, D M, additional, Pawson, T, additional, and Bernstein, A, additional
- Published
- 1991
- Full Text
- View/download PDF
12. The c-fms gene complements the mitogenic defect in mast cells derived from mutant W mice but not mi (microphthalmia) mice.
- Author
-
Dubreuil, P, primary, Forrester, L, additional, Rottapel, R, additional, Reedijk, M, additional, Fujita, J, additional, and Bernstein, A, additional
- Published
- 1991
- Full Text
- View/download PDF
13. W mutant mice with mild or severe developmental defects contain distinct point mutations in the kinase domain of the c-kit receptor.
- Author
-
Reith, A D, primary, Rottapel, R, additional, Giddens, E, additional, Brady, C, additional, Forrester, L, additional, and Bernstein, A, additional
- Published
- 1990
- Full Text
- View/download PDF
14. Suppressor of cytokine signaling-1 inhibits VAV function through protein degradation.
- Author
-
De Sepulveda, P, Ilangumaran, S, and Rottapel, R
- Abstract
Suppressor of cytokine signaling-1 (SOCS1) is an inducible Src homology 2 (SH2)-containing protein that negatively regulates cytokine and growth factor signaling required during thymic development. Recent evidence indicates that SOCS1 interacts with elongins B and C, which are components of a ubiquitin ligase complex, VCB (VHL/elonginC/B), based on the VHL (von Hippel Lindau) tumor suppressor protein. SOCS1 has previously been shown to operate as an inhibitor of Janus kinases. Here we show that SOCS1 has the distinct function of targeting the hematopoietic specific guanine nucleotide exchange factor, VAV, for ubiquitin-mediated protein degradation. VAV and SOCS1 form a protein complex through interactions between the VAV NH(2)-terminal regulatory region and the SH2 domain of SOCS1 in a phosphotyrosine-independent manner. SOCS1 decreases the steady state levels of cotransfected VAV and onco-VAV and reduces the focus forming activity of onco-VAV. SOCS1 stimulates the polyubiquitination of VAV proteins in vivo, which was stabilized by proteasomal inhibitors. These results suggest that SOCS1 programs VAV degradation by acting as a substrate-specific recognition component of a VCB-like ubiquitin ligase complex.
- Published
- 2000
15. Phosphatidylinositol 3-kinase and Ca2+ influx dependence for ligand-stimulated internalization of the c-Kit receptor.
- Author
-
Gommerman, J L, Rottapel, R, and Berger, S A
- Abstract
We have evaluated the role of phosphatidylinositol 3-kinase (PI3-kinase) and Ca2+ influx in ligand-stimulated internalization of the c-Kit receptor. The wild type (wt) c-Kit receptor and YF719, a mutant receptor in which the SH2-mediated binding site for the p85 subunit of PI3-kinase is disrupted, were expressed in DA-1 cells. YF719 internalized with similar kinetics as wt c-Kit although the receptor remained localized close to the plasma membrane. However, in the absence of extracellular Ca2+, or in the presence of the competitive Ca2+ influx blocker Ni2+, the YF719 mutant failed to internalize. Failure to internalize in the absence of Ca2+ was also observed for the wt c-Kit receptor in cells that were pretreated with the PI3-kinase inhibitor, wortmannin. Following stimulation with ligand, clathrin heavy chains were found to co-immunoprecipitate with c-Kit. However, under conditions in which PI3-kinase activity is inhibited and Ca2+ influx is blocked, clathrin failed to co-immunoprecipitate with c-Kit. Our results demonstrate that both Ca2+ influx and PI3-kinase activity influence c-Kit endocytosis, and inhibition of these two signals disrupts the earliest stages of ligand-mediated internalization.
- Published
- 1997
16. Interaction with the phosphotyrosine binding domain/phosphotyrosine interacting domain of SHC is required for the transforming activity of the FLT4/VEGFR3 receptor tyrosine kinase.
- Author
-
Fournier, E, Rosnet, O, Marchetto, S, Turck, C W, Rottapel, R, Pelicci, P G, Birnbaum, D, and Borg, J P
- Abstract
The FLT4 gene encodes two isoforms of a tyrosine kinase receptor, which belongs to the family of receptors for vascular endothelial growth factor. As the result of an alternative processing of primary mRNA transcripts, the long isoform differs from the short isoform by an additional stretch of 65 amino acid residues located at the C terminus and containing three tyrosine residues, Tyr1333, Tyr1337, and Tyr1363. Only the long isoform is endowed with a transforming capacity in fibroblasts. We show that this activity is related to the capacity of the tyrosine 1337-containing sequence to interact with the phosphotyrosine binding domain of the SHC protein. This demonstrates that a functional property of this newly described domain includes relay of mitogenic signals. In addition, it shows that the same receptor can mediate different functions through the optional binding of the phosphotyrosine binding domain and that the alternative use of this domain is sufficient to direct the signal toward different pathways.
- Published
- 1996
17. Phosphatidylinositol-3' kinase is not required for mitogenesis or internalization of the Flt3/Flk2 receptor tyrosine kinase.
- Author
-
Beslu, N, LaRose, J, Casteran, N, Birnbaum, D, Lecocq, E, Dubreuil, P, and Rottapel, R
- Abstract
Flt3/Flk2 is a receptor tyrosine kinase that is expressed on early hematopoietic progenitor cells. Flt3/Flk2 belongs to a family of receptors, including Kit and colony-stimulating factor-1R, which support growth and differentiation within the hematopoietic system. The Flt3/Flk2 ligand, in combination with other growth factors, stimulates the proliferation of hematopoietic progenitors of both lymphoid and myeloid lineages in vitro. We report that phosphatidylinositol 3'-kinase (PI3K) binds to a unique site in the carboxy tail of murine Flt3/Flk2. In distinction to Kit and colony-stimulating factor-1R, mutant receptors unable to couple to PI3K and expressed in rodent fibroblasts or in the interleukin 3-dependent cell line Ba/F3 provide a mitogenic signal comparable to wild-type receptors. Flt3/Flk2 receptors that do not bind to PI3K also normally down-regulate, a function ascribed to PI3K in the context of other receptor systems. These data point to the existence of other unidentified pathways that, alone or in combination with PI3K, transduce these cellular responses following the activation of Flt3/Flk2.
- Published
- 1996
18. Grb2 forms an inducible protein complex with CD28 through a Src homology 3 domain-proline interaction.
- Author
-
Okkenhaug, K and Rottapel, R
- Abstract
CD28 provides a costimulatory signal that results in optimal activation of T cells. The signal transduction pathways necessary for CD28-mediated costimulation are presently unknown. Engagement of CD28 leads to its tyrosine phosphorylation and subsequent binding to Src homology 2 (SH2)-containing proteins including the p85 subunit of phosphatidylinositol 3'-kinase (PI3K); however, the contribution of PI3K to CD28-dependent costimulation remains controversial. Here we show that CD28 is capable of binding the Src homology 3 (SH3) domains of several proteins, including Grb2. The interaction between Grb2 and CD28 is mediated by the binding of Grb2-SH3 domains to the C-terminal diproline motif present in the cytoplasmic domain of CD28. While the affinity of the C-terminal SH3 domain of Grb2 for CD28 is greater than that of the N-terminal SH3 domain, optimal binding requires both SH3 domains. Ligation of CD28, but not tyrosine-phosphorylation, is required for the SH3-mediated binding of Grb2 to CD28. We propose a model whereby the association of Grb2 with CD28 occurs via an inducible SH3-mediated interaction and leads to the recruitment of tyrosine-phosphorylated proteins such as p52(shc) bound to the SH2 domain of Grb2. The inducible interaction of Grb2 to the C-terminal region of CD28 may form the basis for PI3K-independent signaling through CD28.
- Published
- 1998
19. The FLT4 gene encodes a transmembrane tyrosine kinase related to the vascular endothelial growth factor receptor
- Author
-
Galland, F., Karamysheva, A., Pebusque, M. -J, Jean-Paul Borg, Rottapel, R., Dubreuil, P., Rosnet, O., and Birnbaum, D.
- Subjects
Vascular Endothelial Growth Factor A ,Lymphokines ,Base Sequence ,Vascular Endothelial Growth Factors ,Placenta ,Molecular Sequence Data ,Chromosome Mapping ,Receptors, Cell Surface ,Endothelial Growth Factors ,Protein-Tyrosine Kinases ,Vascular Endothelial Growth Factor Receptor-3 ,Cell Line ,Molecular Weight ,Mice ,Animals ,Humans ,Amino Acid Sequence ,Cloning, Molecular - Abstract
Three receptor tyrosine kinases, FLT1, FLK1 and FLT4, contain seven immunoglobin-like domains in their extracellular region and are strongly related by sequence similarities to each other and, to a lesser degree, to the class III receptors CSF1R/FMS, PDGFR, SLFR/KIT and FLT3/FLK2. They constitute a family of receptors putatively involved in the growth regulation of endothelial cells. We describe here the structure and pattern of expression of the human FLT4 gene. Two FLT4 transcripts of 5.8 and 4.5 kb are expressed in the human placenta and several hematopoietic cell lines. In mouse, a 5.8-kb transcript is expressed in a variety of tissues. A translational product 1298 amino acids in length is predicted to be encoded by the largest open reading frame. The FLT4 protein, when transiently expressed in Cos-7 cells and immunoprecipitated with a FLT4-specific rabbit immune serum, has an apparent molecular weight of 170 kDa.
20. Socs1 birds to multiple signalling proteins and suppresses Steel factor-dependent proliferation
- Author
-
Sepulveda, P., Okkenhaug, K., La Rose, J., Hawley, R. G., Patrice Dubreuil, and Rottapel, R.
21. TACC3-TSC2 maintains nuclear envelope structure and controls cell division
- Author
-
Gómez-Baldó L, Schmidt S, Ca, Maxwell, Bonifaci N, Gabaldón T, Po, Vidalain, Senapedis W, Kletke A, Rosing M, Barnekow A, Rottapel R, Capellá G, Vidal M, Aristotelis Astrinidis, Rp, Piekorz, and Ma, Pujana
22. Substrate specificities and identification of a putative binding site for P13K in the carboxy tail of the murine Flt3 receptor tyrosine kinase
- Author
-
Rottapel, R., Turck, C. W., Casteran, N., X. Johne Liu, Birnbaum, D., Pawson, T., and Dubreuil, P.
23. Biochemical characterization of two isoforms of FLT4, a VEGF receptor-related tyrosine kinase
- Author
-
Jean-Paul Borg, deLapeyrière O, Noguchi T, Rottapel R, Dubreuil P, and Birnbaum D
- Subjects
Mice, Inbred C3H ,Macrophage Colony-Stimulating Factor ,Recombinant Fusion Proteins ,Molecular Sequence Data ,Receptor Protein-Tyrosine Kinases ,Receptor, Macrophage Colony-Stimulating Factor ,Receptors, Cell Surface ,Vascular Endothelial Growth Factor Receptor-3 ,Rats ,Mice, Inbred C57BL ,Mice ,Receptors, Vascular Endothelial Growth Factor ,Type C Phospholipases ,Animals ,Receptors, Growth Factor ,Amino Acid Sequence - Abstract
The FLT4 gene encodes a tyrosine kinase receptor related to the two identified receptors for vascular endothelial growth factor (VEGF), FLT1 and FLK1/KDR. Two isoforms of FLT4, differing by their C-terminal ends, have been identified. The long form has 65 additional amino acid residues. We have shown that FLT4 is a highly glycosylated, relatively stable, cell surface associated kinase of approximately 180 kDa. In order to study the signal transduction molecules associated with the FLT4 pathway, and in the absence of a known ligand, we constructed two chimeric molecules (FF4S and FF4L) made of the extracellular region of the CSF1 receptor (Fms gene product) and of the transmembrane and intracellular regions of either form of FLT4. These two chimeric forms were expressed in Rat 2 transfectants. We assayed the ligand-induced capacity of the FF4 short and long forms to sustain growth of Rat 2 cells in semisolid medium. In a soft agar assay, only the long form was able to induce the growth of Rat 2 cells upon ligand treatment. The two forms of FLT4 therefore have different functional capacities. We looked for association and/or phosphorylation of phospholipase C gamma (PLC gamma) and phosphatidylinositol-3'-phosphate (PI3K), after stimulation of the FF4 molecules by CSF1. Finally, we have studied the expression of the Flt4 gene in mouse embryos and in the adult by in situ hybridization. Flt4 transcripts were found at day 12.5 post-coïtum and thereafter, including the adult mouse, predominantly in the pericardium, pleural membranes and in the lung.
24. CaPSID: A bioinformatics platform for computational pathogen sequence identification in human genomes and transcriptomes
- Author
-
Borozan Ivan, Wilson Shane, Blanchette Paola, Laflamme Philippe, Watt Stuart N, Krzyzanowski Paul M, Sircoulomb Fabrice, Rottapel Robert, Branton Philip E, and Ferretti Vincent
- Subjects
Computer applications to medicine. Medical informatics ,R858-859.7 ,Biology (General) ,QH301-705.5 - Abstract
Abstract Background It is now well established that nearly 20% of human cancers are caused by infectious agents, and the list of human oncogenic pathogens will grow in the future for a variety of cancer types. Whole tumor transcriptome and genome sequencing by next-generation sequencing technologies presents an unparalleled opportunity for pathogen detection and discovery in human tissues but requires development of new genome-wide bioinformatics tools. Results Here we present CaPSID (Computational Pathogen Sequence IDentification), a comprehensive bioinformatics platform for identifying, querying and visualizing both exogenous and endogenous pathogen nucleotide sequences in tumor genomes and transcriptomes. CaPSID includes a scalable, high performance database for data storage and a web application that integrates the genome browser JBrowse. CaPSID also provides useful metrics for sequence analysis of pre-aligned BAM files, such as gene and genome coverage, and is optimized to run efficiently on multiprocessor computers with low memory usage. Conclusions To demonstrate the usefulness and efficiency of CaPSID, we carried out a comprehensive analysis of both a simulated dataset and transcriptome samples from ovarian cancer. CaPSID correctly identified all of the human and pathogen sequences in the simulated dataset, while in the ovarian dataset CaPSID’s predictions were successfully validated in vitro.
- Published
- 2012
- Full Text
- View/download PDF
25. The Rho-specific GEF IFC regulates neural precursor fate determination during cortical development
- Author
-
Gauthier-Fisher, A., Lin, D.C., Greeve, M.A., Rottapel, R., Kaplan, D.R., and Miller, F.D.
- Published
- 2008
- Full Text
- View/download PDF
26. Perceptions of extended-release buprenorphine among people who received medication for opioid use disorder in jail: a qualitative study.
- Author
-
Stopka TJ, Rottapel R, Friedmann PD, Pivovarova E, and Evans EA
- Subjects
- Humans, Male, Female, Adult, Middle Aged, Massachusetts, Jails, Prisoners, Interviews as Topic, Narcotic Antagonists administration & dosage, Narcotic Antagonists therapeutic use, Buprenorphine administration & dosage, Buprenorphine therapeutic use, Opioid-Related Disorders drug therapy, Qualitative Research, Delayed-Action Preparations, Opiate Substitution Treatment methods
- Abstract
Background: Incarceration provides an opportunity for health interventions, including opioid use disorder (OUD) treatment and prevention of opioid-related overdoses post-release. All FDA-approved forms of medication for OUD (MOUD) treatment were mandated in several Massachusetts jails in 2019, with some jails offering extended-release buprenorphine (XR-Bup). Little is known about patient perspectives on and experiences with XR-Bup in carceral settings., Methods: We conducted semi-structured interviews in 2022 with community-dwelling people who received MOUD during a recent incarceration in a Massachusetts jail. We asked participants about their experiences with and perspectives on XR-Bup while in jail. Qualitative data were double-coded deductively and reviewed inductively to identify emergent themes, which were structured using the Theoretical Framework of Acceptability (TFA)., Results: Participants (n = 38) had a mean age of 41.5 years, were 86% male, 84% White, 24% Hispanic, and 95% continued to receive MOUD at the time of their interview, including 11% receiving XR-Bup. Participants who viewed XR-Bup favorably appreciated avoiding the taste of sublingual buprenorphine; avoiding procedural difficulties and indignities associated with daily dosing in carceral settings (e.g., mouth checks, stigmatizing treatment from correctional staff); avoiding daily reminders of their addiction; experiencing less withdrawal; having extra time for other activities, such as work; and reduction of diversion of MOUD within the jail setting. Participants who viewed XR-Bup less favorably preferred to maintain their daily dosing routine; liked daily time out of their housing unit; wanted to know what was "going into my body everyday"; and feared needles and adverse events. Participants also reported that jail clinicians used XR-Bup for patients who were previously caught diverting sublingual buprenorphine, suggesting limited patient participation in decision-making around XR-Bup initiation in some jails., Conclusion: People who received MOUD in Massachusetts jails had both favorable and unfavorable views and experiences with XR-Bup. Understanding these preferences can inform protocols in jails that are considering implementation of XR-Bup treatment., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
27. Netrin signaling mediates survival of dormant epithelial ovarian cancer cells.
- Author
-
Perampalam P, MacDonald JI, Zakirova K, Passos DT, Wasif S, Ramos-Valdes Y, Hervieu M, Mehlen P, Rottapel R, Gibert B, Correa RJM, Shepherd TG, and Dick FA
- Subjects
- Humans, Female, Animals, Cell Line, Tumor, Mice, Netrin-1 metabolism, Netrin-1 genetics, Cell Proliferation, Netrin Receptors metabolism, Netrin Receptors genetics, Signal Transduction, Carcinoma, Ovarian Epithelial genetics, Carcinoma, Ovarian Epithelial metabolism, Carcinoma, Ovarian Epithelial pathology, Cell Survival, Ovarian Neoplasms genetics, Ovarian Neoplasms pathology, Ovarian Neoplasms metabolism, Netrins metabolism, Netrins genetics
- Abstract
Dormancy in cancer is a clinical state in which residual disease remains undetectable for a prolonged duration. At a cellular level, rare cancer cells cease proliferation and survive chemotherapy and disseminate disease. We created a suspension culture model of high-grade serous ovarian cancer (HGSOC) dormancy and devised a novel CRISPR screening approach to identify survival genes in this context. In combination with RNA-seq, we discovered the Netrin signaling pathway as critical to dormant HGSOC cell survival. We demonstrate that Netrin-1, -3, and its receptors are essential for low level ERK activation to promote survival, and that Netrin activation of ERK is unable to induce proliferation. Deletion of all UNC5 family receptors blocks Netrin signaling in HGSOC cells and compromises viability during the dormancy step of dissemination in xenograft assays. Furthermore, we demonstrate that Netrin-1 and -3 overexpression in HGSOC correlates with poor outcome. Specifically, our experiments reveal that Netrin overexpression elevates cell survival in dormant culture conditions and contributes to greater spread of disease in a xenograft model of abdominal dissemination. This study highlights Netrin signaling as a key mediator HGSOC cancer cell dormancy and metastasis., Competing Interests: PP, JM, KZ, DP, SW, YR, MH, RR, BG, RC, TS, FD No competing interests declared, PM Founder of Netris Pharma, (© 2023, Perampalam et al.)
- Published
- 2024
- Full Text
- View/download PDF
28. Author Correction: Inhibition of nicotinamide dinucleotide salvage pathway counters acquired and intrinsic poly(ADP-ribose) polymerase inhibitor resistance in high-grade serous ovarian cancer.
- Author
-
Sauriol SA, Carmona E, Udaskin ML, Radulovich N, Leclerc-Desaulniers K, Rottapel R, Oza AM, Lheureux S, Provencher DM, and Mes-Masson AM
- Published
- 2024
- Full Text
- View/download PDF
29. Scaffold protein SH3BP2 signalosome is pivotal for immune activation in nephrotic syndrome.
- Author
-
Srivastava T, Garola RE, Zhou J, Boinpelly VC, Rezaiekhaligh MH, Joshi T, Jiang Y, Ebadi D, Sharma S, Sethna C, Staggs VS, Sharma R, Gipson DS, Hao W, Wang Y, Mariani LH, Hodgin JB, Rottapel R, Yoshitaka T, Ueki Y, and Sharma M
- Subjects
- Animals, Humans, Mice, Adaptor Proteins, Signal Transducing genetics, Adaptor Proteins, Signal Transducing metabolism, Kidney pathology, Kidney Glomerulus pathology, Mice, Transgenic, Phospholipase C gamma genetics, Phospholipase C gamma metabolism, Glomerulosclerosis, Focal Segmental genetics, Glomerulosclerosis, Focal Segmental metabolism, Nephrosis, Lipoid pathology, Nephrotic Syndrome metabolism
- Abstract
Despite clinical use of immunosuppressive agents, the immunopathogenesis of minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) remains unclear. Src homology 3-binding protein 2 (SH3BP2), a scaffold protein, forms an immune signaling complex (signalosome) with 17 other proteins, including phospholipase Cγ2 (PLCγ2) and Rho-guanine nucleotide exchange factor VAV2 (VAV2). Bioinformatic analysis of human glomerular transcriptome (Nephrotic Syndrome Study Network cohort) revealed upregulated SH3BP2 in MCD and FSGS. The SH3BP2 signalosome score and downstream MyD88, TRIF, and NFATc1 were significantly upregulated in MCD and FSGS. Immune pathway activation scores for Toll-like receptors, cytokine-cytokine receptor, and NOD-like receptors were increased in FSGS. Lower SH3BP2 signalosome score was associated with MCD, higher estimated glomerular filtration rate, and remission. Further work using Sh3bp2KI/KI transgenic mice with a gain-in-function mutation showed ~6-fold and ~25-fold increases in albuminuria at 4 and 12 weeks, respectively. Decreased serum albumin and unchanged serum creatinine were observed at 12 weeks. Sh3bp2KI/KI kidney morphology appeared normal except for increased mesangial cellularity and patchy foot process fusion without electron-dense deposits. SH3BP2 co-immunoprecipitated with PLCγ2 and VAV2 in human podocytes, underscoring the importance of SH3BP2 in immune activation. SH3BP2 and its binding partners may determine the immune activation pathways resulting in podocyte injury leading to loss of the glomerular filtration barrier.
- Published
- 2024
- Full Text
- View/download PDF
30. Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT).
- Author
-
Genta S, Lajkosz K, Yee NR, Spiliopoulou P, Heirali A, Hansen AR, Siu LL, Saibil S, Stayner LA, Yanekina M, Sauder MB, Keshavarzi S, Salawu A, Vornicova O, Butler MO, Bedard PL, Razak ARA, Rottapel R, Chruscinski A, Coburn B, and Spreafico A
- Subjects
- Humans, Prospective Studies, Immunoglobulin G, Immunoglobulin M, Retrospective Studies, Immune Checkpoint Inhibitors adverse effects, Autoantigens
- Abstract
Background: Immune-checkpoint inhibitors (ICI) can lead to immune-related adverse events (irAEs) in a significant proportion of patients. The mechanisms underlying irAEs development are mostly unknown and might involve multiple immune effectors, such as T cells, B cells and autoantibodies (AutoAb)., Methods: We used custom autoantigen (AutoAg) microarrays to profile AutoAb related to irAEs in patients receiving ICI. Plasma was collected before and after ICI from cancer patients participating in two clinical trials (NCT03686202, NCT02644369). A one-time collection was obtained from healthy controls for comparison. Custom arrays with 162 autoAg were used to detect IgG and IgM reactivities. Differences of median fluorescent intensity (MFI) were analyzed with Wilcoxon sign rank test and Kruskal-Wallis test. MFI 500 was used as threshold to define autoAb reactivity., Results: A total of 114 patients and 14 healthy controls were included in this study. irAEs of grade (G) ≥ 2 occurred in 37/114 patients (32%). We observed a greater number of IgG and IgM reactivities in pre-ICI collections from patients versus healthy controls (62 vs 32 p < 0.001). Patients experiencing irAEs G ≥ 2 demonstrated pre-ICI IgG reactivity to a greater number of AutoAg than patients who did not develop irAEs (39 vs 33 p = 0.040). We observed post-treatment increase of IgM reactivities in subjects experiencing irAEs G ≥ 2 (29 vs 35, p = 0.021) and a decrease of IgG levels after steroids (38 vs 28, p = 0.009)., Conclusions: Overall, these results support the potential role of autoAb in irAEs etiology and evolution. A prospective study is ongoing to validate our findings (NCT04107311)., (© 2023. Italian National Cancer Institute ‘Regina Elena’.)
- Published
- 2023
- Full Text
- View/download PDF
31. Pharmacologic inhibition of PARP5, but not that of PARP1 or 2, promotes cytokine production and osteoclastogenesis through different pathways.
- Author
-
Asano Y, Matsumoto Y, He F, Katsuyama T, Katsuyama E, Tsuji S, Kamioka H, La Rose J, Rottapel R, and Wada J
- Subjects
- Humans, Mice, Animals, Osteogenesis, NF-kappa B metabolism, Cytokines metabolism, Inflammation, Poly (ADP-Ribose) Polymerase-1 therapeutic use, beta Catenin therapeutic use, Lipopolysaccharides pharmacology
- Abstract
Objectives: PARPs, which are members of the poly(ADP-ribose) polymerase superfamily, promote tumorigenesis and tumour-associated inflammation and are thus therapeutic targets for several cancers. The aim of the present study is to investigate the mechanistic insight into the roles PARPs for inflammation., Methods: Primary murine macrophages were cultured in the presence or absence of the PARP5 inhibitor NVP-TNKS656 to examine the role of PARP5 for cytokine production., Results: In contrast to the roles of other PARPs for induction of inflammation, we found in the present study that pharmacologic inhibition of PARP5 induces production of inflammatory cytokines in primary murine macrophages. We found that treatment with the PARP5 inhibitor NVP-TNKS656 in macrophages enhanced steady-state and LPS-mediated cytokine production through degradation of IκBα and subsequent nuclear translocation of NF-κB. We also found that pharmacologic inhibition of PARP5 stabilises the adaptor protein 3BP2, a substrate of PARP5, and that accelerated cytokine production induced by PARP5 inhibition was rescued in 3BP2-deleted macrophages. Additionally, we found that LPS increases the expression of 3BP2 and AXIN1, a negative regulator of β-catenin, through suppression of PARP5 transcripts in macrophages, leading to further activation of cytokine production and inhibition of β-catenin-mediated cell proliferation, respectively. Lastly, we found that PARP5 inhibition in macrophages promotes osteoclastogenesis through stabilisation of 3BP2 and AXIN1, leading to activation of SRC and suppression of β-catenin, respectively., Conclusions: Our results show that pharmacologic inhibition of PARP5 against cancers unexpectedly induces adverse autoinflammatory side effects through activation of innate immunity, unlike inhibition of other PARPs.
- Published
- 2023
- Full Text
- View/download PDF
32. PARsylation-mediated ubiquitylation: lessons from rare hereditary disease Cherubism.
- Author
-
Matsumoto Y and Rottapel R
- Subjects
- Humans, Ubiquitination, Signal Transduction, Adaptor Proteins, Signal Transducing genetics, Adaptor Proteins, Signal Transducing metabolism, Tankyrases genetics, Tankyrases chemistry, Tankyrases metabolism, Cherubism genetics, Cherubism metabolism
- Abstract
Modification of proteins by ADP-ribose (PARsylation) is catalyzed by the poly(ADP-ribose) polymerase (PARP) family of enzymes exemplified by PARP1, which controls chromatin organization and DNA repair. Additionally, PARsylation induces ubiquitylation and proteasomal degradation of its substrates because PARsylation creates a recognition site for E3-ubiquitin ligase. The steady-state levels of the adaptor protein SH3-domain binding protein 2 (3BP2) is negatively regulated by tankyrase (PARP5), which coordinates ubiquitylation of 3BP2 by the E3-ligase ring finger protein 146 (RNF146). 3BP2 missense mutations uncouple 3BP2 from tankyrase-mediated negative regulation and cause Cherubism, an autosomal dominant autoinflammatory disorder associated with craniofacial dysmorphia. In this review, we summarize the diverse biological processes, including bone dynamics, metabolism, and Toll-like receptor (TLR) signaling controlled by tankyrase-mediated PARsylation of 3BP2, and highlight the therapeutic potential of this pathway., Competing Interests: Declaration of interests None declared by authors., (Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
33. Adapting Brief Behavioral Treatment for Insomnia for Former National Football League Players: A Pilot Study.
- Author
-
Wanberg LJ, Thomas SJ, Reid M, Rottapel R, von Ash T, Jones N, Brar L, Beidas R, Rueschman M, Edwards RR, Buysse DJ, Redline S, and Bertisch SM
- Subjects
- Humans, Behavior Therapy, Pilot Projects, Treatment Outcome, Chronic Pain, Football, Sleep Initiation and Maintenance Disorders therapy
- Abstract
Objectives: Insomnia is highly prevalent among persons with chronic pain. Although cognitive behavioral therapy for insomnia is recommended as first-line treatment for insomnia, it is underutilized. We tested the feasibility of a potentially scalable alternative - Brief Behavioral Therapy for Insomnia (BBTI) for former National Football League (NFL) players, a group with a high prevalence of chronic pain. We assessed changes in sleep, pain, and psychological health., Methods: Single-arm clinical trial of an adapted telephone-delivered BBTI intervention in 40 former NFL players with insomnia. We collected data on changes in sleep, pain, and psychological health outcomes., Results: Among former players (30% racial/ethnic minorities), BBTI was both acceptable and feasible. BBTI was associated with improvements in sleep disturbance (primary exploratory sleep outcome, mean T-score change -6.2, 95% CI: -7.6, -4.8), sleep-related impairment (mean T-score change -5.7, 95% CI: -7.9, -3.5) and insomnia severity (mean change -5.3, 95% CI: -6.8, -3.5) post-intervention. Improvements were maintained at 2-months. BBTI was also associated with improvements in pain interference and intensity, but not psychological health., Conclusion: An adapted telephone-delivered BBTI is acceptable and feasible among retired players with a range of insomnia symptoms and shows promise for improving sleep and pain. These data support the need for future trials assessing BBTI's effect on both sleep and pain outcomes.
- Published
- 2023
- Full Text
- View/download PDF
34. COVID-19 impact on opioid overdose after jail release in Massachusetts.
- Author
-
Friedmann PD, Dunn D, Michener P, Bernson D, Stopka TJ, Pivovarova E, Ferguson WJ, Rottapel R, Hoskinson R Jr, Wilson D, and Evans EA
- Abstract
Introduction: Release from incarceration is a high-risk period for opioid overdose. Concern about COVID-19 spread in jails led to early releases; it is unknown whether pandemic era releases of persons with opioid use disorder (OUD) contributed to increases in community overdose rates., Methods: Observational data compared overdose rates three months after release among jailed persons with OUD released before (9/1/2019-3/9/2020) and during the pandemic (3/10/2020-8/10/2020) from seven jails in Massachusetts. Data on overdoses come from the Massachusetts Ambulance Trip Record Information System and Registry of Vital Records Death Certificate file. Other information came from jail administrative data. Logistic models regressed overdose on release period, controlling for MOUD received, county of release, race/ethnicity, sex, age, and prior overdose., Results: Pandemic releases with OUD had a higher risk of fatal overdose (adjusted odds ratio [aOR] 3.06; 95% CI, 1.49 to 6.26); 20 persons released with OUD (1.3%) experienced a fatal overdose within three months of release, versus 14 (0.5%) pre-pandemic. MOUD had no detectable relationship with overdose mortality. Pandemic release did not impact non-fatal overdose rates (aOR 0.84; 95% CI 0.60 to 1.18), though in-jail methadone treatment was protective (aOR 0.34; 95% CI 0.18 to 0.67)., Conclusions: Persons with OUD released from jail during the pandemic experienced higher overdose mortality compared to pre-pandemic, but the number of deaths was small. They did not experience significantly different rates of non-fatal overdose. Early jail releases during the pandemic were unlikely to explain much, if any, of the observed increase in community overdoses in Massachusetts., Competing Interests: No conflict declared., (© 2023 The Authors. Published by Elsevier B.V.)
- Published
- 2023
- Full Text
- View/download PDF
35. Inhibition of nicotinamide dinucleotide salvage pathway counters acquired and intrinsic poly(ADP-ribose) polymerase inhibitor resistance in high-grade serous ovarian cancer.
- Author
-
Sauriol SA, Carmona E, Udaskin ML, Radulovich N, Leclerc-Desaulniers K, Rottapel R, Oza AM, Lheureux S, Provencher DM, and Mes-Masson AM
- Subjects
- Humans, Animals, Mice, Female, Poly(ADP-ribose) Polymerase Inhibitors pharmacology, Poly(ADP-ribose) Polymerase Inhibitors therapeutic use, Niacinamide, Dinucleoside Phosphates, Antineoplastic Agents, Ovarian Neoplasms drug therapy
- Abstract
Epithelial ovarian cancer is the most lethal gynecological malignancy, owing notably to its high rate of therapy-resistant recurrence in spite of good initial response to chemotherapy. Although poly(ADP-ribose) polymerase inhibitors (PARPi) have shown promise for ovarian cancer treatment, extended therapy usually leads to acquired PARPi resistance. Here we explored a novel therapeutic option to counter this phenomenon, combining PARPi and inhibitors of nicotinamide phosphoribosyltransferase (NAMPT). Cell-based models of acquired PARPi resistance were created through an in vitro selection procedure. Using resistant cells, xenograft tumors were grown in immunodeficient mice, while organoid models were generated from primary patient tumor samples. Intrinsically PARPi-resistant cell lines were also selected for analysis. Our results show that treatment with NAMPT inhibitors effectively sensitized all in vitro models to PARPi. Adding nicotinamide mononucleotide, the resulting NAMPT metabolite, abrogated the therapy-induced cell growth inhibition, demonstrating the specificity of the synergy. Treatment with olaparib (PARPi) and daporinad (NAMPT inhibitor) depleted intracellular NAD+ , induced double-strand DNA breaks, and promoted apoptosis as monitored by caspase-3 cleavage. The two drugs were also synergistic in mouse xenograft models and clinically relevant patient-derived organoids. Therefore, in the context of PARPi resistance, NAMPT inhibition could offer a promising new option for ovarian cancer patients., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
36. E3-ubiquitin ligases and recent progress in osteoimmunology.
- Author
-
Asano Y, Matsumoto Y, Wada J, and Rottapel R
- Subjects
- Animals, Child, Humans, Ubiquitination, Ubiquitin metabolism, Ubiquitin-Activating Enzymes genetics, Ubiquitin-Protein Ligases metabolism, Cherubism
- Abstract
Ubiquitin-mediated proteasomal degradation is a post-transcriptional protein modification that is comprised of various components including the 76-amino acid protein ubiquitin (Ub), Ub-activating enzyme (E1), Ub-conjugating enzyme (E2), ubiquitin ligase (E3), deubiquitinating enzyme (DUB) and proteasome. We and others have recently provided genetic evidence showing that E3-ubiquitin ligases are associated with bone metabolism, the immune system and inflammation through ubiquitylation and subsequent degradation of their substrates. Dysregulation of the E3-ubiquitin ligase RNF146-mediated degradation of the adaptor protein 3BP2 (SH3 domain-binding protein 2) causes cherubism, an autosomal dominant disorder associated with severe inflammatory craniofacial dysmorphia syndrome in children. In this review, on the basis of our discoveries in cherubism, we summarize new insights into the roles of E3-ubiquitin ligases in the development of human disorders caused by an abnormal osteoimmune system by highlighting recent genetic evidence obtained in both human and animal model studies., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Asano, Matsumoto, Wada and Rottapel.)
- Published
- 2023
- Full Text
- View/download PDF
37. Translational Control by 4E-BP1/2 Suppressor Proteins Regulates Mitochondrial Biosynthesis and Function during CD8 + T Cell Proliferation.
- Author
-
Dimitriou ID, Meiri D, Jitkova Y, Elford AR, Koritzinsky M, Schimmer AD, Ohashi PS, Sonenberg N, and Rottapel R
- Subjects
- Animals, CD8-Positive T-Lymphocytes metabolism, Cell Cycle Proteins metabolism, Cell Proliferation, Mammals genetics, Mice, Organelle Biogenesis, Phosphatidylinositol 3-Kinases metabolism, Phosphorylation, Protein Biosynthesis, Eukaryotic Initiation Factors genetics, Eukaryotic Initiation Factors metabolism, Phosphoproteins metabolism
- Abstract
CD8
+ T cell proliferation and differentiation into effector and memory states are high-energy processes associated with changes in cellular metabolism. CD28-mediated costimulation of T cells activates the PI3K/AKT/mammalian target of rapamycin signaling pathway and induces eukaryotic translation initiation factor 4E-dependent translation through the derepression by 4E-BP1 and 4E-BP2. In this study, we demonstrate that 4E-BP1/2 proteins are required for optimum proliferation of mouse CD8+ T cells and the development of an antiviral effector function. We show that translation of genes encoding mitochondrial biogenesis is impaired in T cells derived from 4E-BP1/2-deficient mice. Our findings demonstrate an unanticipated role for 4E-BPs in regulating a metabolic program that is required for cell growth and biosynthesis during the early stages of CD8+ T cell expansion., (Copyright © 2022 by The American Association of Immunologists, Inc.)- Published
- 2022
- Full Text
- View/download PDF
38. Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer.
- Author
-
Marastoni S, Madariaga A, Pesic A, Nair SN, Li ZJ, Shalev Z, Ketela T, Colombo I, Mandilaras V, Cabanero M, Bruce JP, Li X, Garg S, Wang L, Chen EX, Gill S, Dhani NC, Zhang W, Pintilie M, Bowering V, Koritzinsky M, Rottapel R, Wouters BG, Oza AM, Joshua AM, and Lheureux S
- Subjects
- Humans, Female, Itraconazole pharmacology, Hydroxychloroquine pharmacology, Antifungal Agents metabolism, Carcinoma, Ovarian Epithelial drug therapy, Drug Repositioning, Chloroquine metabolism, Lysosomes, Homeostasis, Antineoplastic Agents pharmacology, Ovarian Neoplasms drug therapy
- Abstract
Drug repurposing is an attractive option for oncology drug development. Itraconazole is an antifungal ergosterol synthesis inhibitor that has pleiotropic actions including cholesterol antagonism, inhibition of Hedgehog and mTOR pathways. We tested a panel of 28 epithelial ovarian cancer (EOC) cell lines with itraconazole to define its spectrum of activity. To identify synthetic lethality in combination with itraconazole, a whole-genome drop-out genome-scale clustered regularly interspaced short palindromic repeats sensitivity screen in two cell lines (TOV1946 and OVCAR5) was performed. On this basis, we conducted a phase I dose-escalation study assessing the combination of itraconazole and hydroxychloroquine in patients with platinum refractory EOC (NCT03081702). We identified a wide spectrum of sensitivity to itraconazole across the EOC cell lines. Pathway analysis showed significant involvement of lysosomal compartments, the trans-golgi network and late endosomes/lysosomes; similar pathways are phenocopied by the autophagy inhibitor, chloroquine. We then demonstrated that the combination of itraconazole and chloroquine displayed Bliss defined synergy in EOC cancer cell lines. Furthermore, there was an association of cytotoxic synergy with the ability to induce functional lysosome dysfunction, by chloroquine. Within the clinical trial, 11 patients received at least one cycle of itraconazole and hydroxychloroquine. Treatment was safe and feasible with the recommended phase II dose of 300 and 600 mg twice daily, respectively. No objective responses were detected. Pharmacodynamic measurements on serial biopsies demonstrated limited pharmacodynamic impact. In vitro , itraconazole and chloroquine have synergistic activity and exert a potent antitumor effect by affecting lysosomal function. The drug combination had no clinical antitumor activity in dose escalation., Significance: The combination of the antifungal drug itraconazole with antimalarial drug hydroxychloroquine leads to a cytotoxic lysosomal dysfunction, supporting the rational for further research on lysosomal targeting in ovarian cancer., Competing Interests: S. Marastoni reports a Canadian patent number 3,116,081 pending. A. Madariaga reports personal fees from Clovis and AstraZeneca outside the submitted work. Z.J. Li reports a Canadian patent number to CA3,116,081 pending. I. Colombo reports personal fees from MSD; other from GSK, AstraZeneca, MSD, Bayer, and Oasmia outside the submitted work. J.P. Bruce reports other from Bowhead Health outside the submitted work. M. Koritzinsky reports other from The Princess Margaret Cancer Foundation during the conduct of the study; in addition, M. Koritzinsky has a Canadian patent number number 3,116,081 pending. B.G. Wouters reports grants from Ontario Institute for Cancer Research, Canadian Institutes for Cancer Research, and Princess Margaret Cancer Foundation during the conduct of the study; other from Northern Biologics outside the submitted work; in addition, B.G. Wouters has a Canadian patent number 3,116,081 issued. A.M. Oza is PI and on clinical trial steer- ing committees for trials with Clovis, GSK, AstraZeneca—all uncompensated. A.M. Oza is uncompensated CEO of Ozmosis Research, a Not For Profit Clin- ical Trials Management company associated with UHN. A.M. Joshua reports non-financial support from Mayne Pharma during the conduct of the study; other from Pricilium outside the submitted work; in addition, A.M. Joshua has a Canadian patent number 3,116,081 pending. S. Lheureux reports grants from OICR - TRI Ovarian Cancer during the conduct of the study; grants and personal fees from AstraZeneca, GSK; personal fees from Eisai, Merck, Shattuck Labs; grants from Roche, and outside the submitted work. No other disclosures were reported., (© 2022 The Authors; Published by the American Association for Cancer Research.)
- Published
- 2022
- Full Text
- View/download PDF
39. Tankyrase represses autoinflammation through the attenuation of TLR2 signaling.
- Author
-
Matsumoto Y, Dimitriou ID, La Rose J, Lim M, Camilleri S, Law N, Adissu HA, Tong J, Moran MF, Chruscinski A, He F, Asano Y, Katsuyama T, Sada KE, Wada J, and Rottapel R
- Subjects
- Adaptor Proteins, Signal Transducing metabolism, Animals, Mice, Signal Transduction, Syk Kinase metabolism, Autoimmune Diseases genetics, Inflammation genetics, Tankyrases genetics, Tankyrases metabolism, Toll-Like Receptor 2 genetics, Toll-Like Receptor 2 metabolism
- Abstract
Dysregulation of Toll-like receptor (TLR) signaling contributes to the pathogenesis of autoimmune diseases. Here, we provide genetic evidence that tankyrase, a member of the poly(ADP-ribose) polymerase (PARP) family, negatively regulates TLR2 signaling. We show that mice lacking tankyrase in myeloid cells developed severe systemic inflammation with high serum inflammatory cytokine levels. We provide mechanistic evidence that tankyrase deficiency resulted in tyrosine phosphorylation and activation of TLR2 and show that phosphorylation of tyrosine 647 within the TIR domain by SRC and SYK kinases was critical for TLR2 stabilization and signaling. Last, we show that the elevated cytokine production and inflammation observed in mice lacking tankyrase in myeloid cells were dependent on the adaptor protein 3BP2, which is required for SRC and SYK activation. These data demonstrate that tankyrase provides a checkpoint on the TLR-mediated innate immune response.
- Published
- 2022
- Full Text
- View/download PDF
40. N6-Methyladenosine Reader YTHDF1 Promotes ARHGEF2 Translation and RhoA Signaling in Colorectal Cancer.
- Author
-
Wang S, Gao S, Zeng Y, Zhu L, Mo Y, Wong CC, Bao Y, Su P, Zhai J, Wang L, Soares F, Xu X, Chen H, Hezaveh K, Ci X, He A, McGaha T, O'Brien C, Rottapel R, Kang W, Wu J, Zheng G, Cai Z, Yu J, and He HH
- Subjects
- Adenosine analogs & derivatives, Adenosine metabolism, Animals, Carcinogenesis genetics, Humans, Liposomes, Mice, Nanoparticles, RNA, Small Interfering, RNA-Binding Proteins genetics, RNA-Binding Proteins metabolism, Rho Guanine Nucleotide Exchange Factors genetics, Rho Guanine Nucleotide Exchange Factors metabolism, rhoA GTP-Binding Protein genetics, rhoA GTP-Binding Protein metabolism, Colorectal Neoplasms pathology, Gene Expression Regulation, Neoplastic
- Abstract
Background & Aims: N6-methyladenosine (m
6 A) governs the fate of RNAs through m6 A readers. Colorectal cancer (CRC) exhibits aberrant m6 A modifications and expression of m6 A regulators. However, how m6 A readers interpret oncogenic m6 A methylome to promote malignant transformation remains to be illustrated., Methods: YTH N6-methyladenosine RNA binding protein 1 (Ythdf1) knockout mouse was generated to determine the effect of Ythdf1 in CRC tumorigenesis in vivo. Multiomic analysis of RNA-sequencing, m6 A methylated RNA immunoprecipitation sequencing, YTHDF1 RNA immunoprecipitation sequencing, and proteomics were performed to unravel targets of YTHDF1 in CRC. The therapeutic potential of targeting YTHDF1-m6 A-Rho/Rac guanine nucleotide exchange factor 2 (ARHGEF2) was evaluated using small interfering RNA (siRNA) encapsulated by lipid nanoparticles (LNP)., Results: DNA copy number gain of YTHDF1 is a frequent event in CRC and contributes to its overexpression. High expression of YTHDF1 is significantly associated with metastatic gene signature in patient tumors. Ythdf1 knockout in mice dampened tumor growth in an inflammatory CRC model. YTHDF1 promotes cell growth in CRC cell lines and primary organoids and lung and liver metastasis in vivo. Integrative multiomics analysis identified RhoA activator ARHGEF2 as a key downstream target of YTHDF1. YTHDF1 binds to m6 A sites of ARHGEF2 messenger RNA, resulting in enhanced translation of ARHGEF2. Ectopic expression of ARHGEF2 restored impaired RhoA signaling, cell growth, and metastatic ability both in vitro and in vivo caused by YTHDF1 loss, verifying that ARHGEF2 is a key target of YTHDF1. Finally, ARHGEF2 siRNA delivered by LNP significantly suppressed tumor growth and metastasis in vivo., Conclusions: We identify a novel oncogenic epitranscriptome axis of YTHDF1-m6 A-ARHGEF2, which regulates CRC tumorigenesis and metastasis. siRNA-delivering LNP drug validated the therapeutic potential of targeting this axis in CRC., (Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF
41. Author Correction: Gain-of-function variants in SYK cause immune dysregulation and systemic inflammation in humans and mice.
- Author
-
Wang L, Aschenbrenner D, Zeng Z, Cao X, Mayr D, Mehta M, Capitani M, Warner N, Pan J, Wang L, Li Q, Zuo T, Cohen-Kedar S, Lu J, Ardy RC, Mulder DJ, Dissanayake D, Peng K, Huang Z, Li X, Wang Y, Wang X, Li S, Bullers S, Gammage AN, Warnatz K, Schiefer AI, Krivan G, Goda V, Kahr WHA, Lemaire M, Lu CY, Siddiqui I, Surette MG, Kotlarz D, Engelhardt KR, Griffin HR, Rottapel R, Decaluwe H, Laxer RM, Proietti M, Hambleton S, Elcombe S, Guo CH, Grimbacher B, Dotan I, Ng SC, Freeman SA, Snapper SB, Klein C, Boztug K, Huang Y, Li D, Uhlig HH, and Muise AM
- Published
- 2022
- Full Text
- View/download PDF
42. Anticardiolipin and other antiphospholipid antibodies in critically ill COVID-19 positive and negative patients.
- Author
-
Trahtemberg U, Rottapel R, Dos Santos CC, Slutsky AS, Baker A, and Fritzler MJ
- Subjects
- Aged, Antibodies, Anticardiolipin blood, Antibodies, Antiphospholipid blood, Antiphospholipid Syndrome blood, Antiphospholipid Syndrome complications, COVID-19 blood, COVID-19 complications, Critical Illness, Female, Humans, Male, Middle Aged, SARS-CoV-2, Antibodies, Anticardiolipin immunology, Antibodies, Antiphospholipid immunology, Antiphospholipid Syndrome immunology, COVID-19 immunology
- Abstract
Background: Reports of severe COVID-19 being associated with thrombosis, antiphospholipid antibodies (APLA), and antiphospholipid syndrome have yielded disparate conclusions. Studies comparing patients with COVID-19 with contemporaneous controls of similar severity are lacking., Methods: 22 COVID-19
+ and 20 COVID-19- patients with respiratory failure admitted to intensive care were studied longitudinally. Demographic and clinical data were obtained from the day of admission. APLA testing included anticardiolipin (aCL), anti-β2glycoprotien 1 (β2GP1), antidomain 1 β2GP1 and antiphosphatidyl serine/prothrombin complex. Antinuclear antibodies (ANAs) were detected by immunofluorescence and antibodies to cytokines by a commercially available multiplexed array. Analysis of variance was used for continuous variables and Fisher's exact test was used for categorical variables with α=0.05 and the false discovery rate at q=0.05., Results: APLAs were predominantly IgG aCL (48%), followed by IgM (21%) in all patients, with a tendency towards higher frequency among the COVID-19+ . aCL was not associated with surrogate markers of thrombosis but IgG aCL was strongly associated with worse disease severity and higher ANA titres regardless of COVID-19 status. An association between aCL and anticytokine autoantibodies tended to be higher among the COVID-19+ ., Conclusions: Positive APLA serology was associated with more severe disease regardless of COVID-19 status., Trial Registration Number: NCT04747782., Competing Interests: Competing interests: MJF is the Director of MitogenDx. MJF is a consultant for and received speaking honoraria from Inova Diagnostics Inc (San Diego, California, USA) and Werfen International (Barcelona, Spain). All the other authors have no disclosures to declare., (© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)- Published
- 2021
- Full Text
- View/download PDF
43. Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian Research Group of Rheumatology in Immuno-Oncology.
- Author
-
Hoa S, Laaouad L, Roberts J, Ennis D, Ye C, Al Jumaily K, Pope J, Nevskaya T, Saltman A, Himmel M, Rottapel R, Ly C, Colmegna I, Fifi-Mah A, Maltez N, Tisseverasinghe A, Hudson M, and Jamal S
- Subjects
- Canada, Female, Humans, Immunosuppressive Agents immunology, Male, Medical Oncology methods, Middle Aged, Prospective Studies, Retrospective Studies, Rheumatology methods, Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal immunology, Autoimmune Diseases immunology, Immunotherapy adverse effects, Lung Neoplasms immunology, Melanoma immunology, Programmed Cell Death 1 Receptor immunology
- Abstract
Background: Limited data are available on the safety and efficacy of immune checkpoint inhibitors (ICI) in patients with preexisting autoimmune diseases (PAD)., Methods: Retrospective study of patients with PAD referred for rheumatologic evaluation prior to starting or during immunotherapy between January 2013 and July 2019 from 10 academic sites across Canada. Data were extracted by chart review using a standardized form., Results: Twenty-seven patients with PAD on ICI therapy were identified. The most common PADs were rheumatoid arthritis (30%), psoriasis/psoriatic arthritis (30%), inflammatory bowel disease (IBD, 15%) and axial spondyloarthritis (11%), and the most frequently observed cancers were lung cancer and melanoma. All patients received anti-PD-1 therapies, and 2 received additional sequential anti-CTLA-4 therapy. PAD exacerbations occurred in 52% over a median (IQR) follow-up of 11.0 (6.0-17.5) months, with 14% being severe, 57% requiring corticosteroids, 50% requiring immunosuppression and 14% requiring ICI discontinuation. Flares were generally more frequent and severe in patients who previously required more intensive immunosuppression (i.e., biologics). Flares occurred despite background immunosuppression at the time of ICI initiation. In patients with preexisting psoriasis, IBD and axial spondyloarthritis, rheumatic immune-related adverse events (irAEs), mostly polyarthritis and tenosynovitis, were frequently observed. Tumor progression was not associated with exposure to immunosuppressive drugs before or after ICI initiation and was numerically less frequent in patients with irAEs., Conclusion: PAD exacerbations in the context of ICI treatment are common, although generally mild, and occur despite background immunosuppression. Exacerbations are more frequent and severe in patients on more intensive immunosuppressive therapies pre-immunotherapy., (© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature.)
- Published
- 2021
- Full Text
- View/download PDF
44. Corrigendum: RUNX2 Phosphorylation by Tyrosine Kinase ABL Promotes Breast Cancer Invasion.
- Author
-
He F, Matsumoto Y, Asano Y, Yamamura Y, Katsuyama T, Rose J, Tomonobu N, Komalasari NLGY, Sakaguchi M, Rottapel R, and Wada J
- Abstract
[This corrects the article DOI: 10.3389/fonc.2021.665273.]., (Copyright © 2021 He, Matsumoto, Asano, Yamamura, Katsuyama, Rose, Tomonobu, Komalasari, Sakaguchi, Rottapel and Wada.)
- Published
- 2021
- Full Text
- View/download PDF
45. Tankyrase regulates epithelial lumen formation via suppression of Rab11 GEFs.
- Author
-
Chandrakumar AA, Coyaud É, Marshall CB, Ikura M, Raught B, and Rottapel R
- Subjects
- Guanine Nucleotide Exchange Factors, Humans, Protein Binding, Signal Transduction genetics, Tankyrases genetics, Adaptor Proteins, Signal Transducing genetics, Sialoglycoproteins genetics, Ubiquitin-Protein Ligases genetics, rab GTP-Binding Proteins genetics
- Abstract
Rab11 GTPase proteins are required for cytokinesis, ciliogenesis, and lumenogenesis. Rab11a is critical for apical delivery of podocalyxin (PODXL) during lumen formation in epithelial cells. SH3BP5 and SH3BP5L are guanine nucleotide exchange factors (GEFs) for Rab11. We show that SH3BP5 and SH3BP5L are required for activation of Rab11a and cyst lumen formation. Using proximity-dependent biotin identification (BioID) interaction proteomics, we have identified SH3BP5 and its paralogue SH3BP5L as new substrates of the poly-ADP-ribose polymerase Tankyrase and the E3 ligase RNF146. We provide data demonstrating that epithelial polarity via cyst lumen formation is governed by Tankyrase, which inhibits Rab11a activation through the suppression of SH3BP5 and SH3BP5L. RNF146 reduces Tankyrase protein abundance and restores Rab11a activation and lumen formation. Thus, Rab11a activation is controlled by a signaling pathway composed of the sequential inhibition of SH3BP5 paralogues by Tankyrase, which is itself suppressed by RNF146., (© 2021 Chandrakumar et al.)
- Published
- 2021
- Full Text
- View/download PDF
46. RUNX2 Phosphorylation by Tyrosine Kinase ABL Promotes Breast Cancer Invasion.
- Author
-
He F, Matsumoto Y, Asano Y, Yamamura Y, Katsuyama T, La Rose J, Tomonobu N, Komalasari NLGY, Sakaguchi M, Rottapel R, and Wada J
- Abstract
Activity of transcription factors is normally regulated through interaction with other transcription factors, chromatin remodeling proteins and transcriptional co-activators. In distinction to these well-established transcriptional controls of gene expression, we have uncovered a unique activation model of transcription factors between tyrosine kinase ABL and RUNX2, an osteoblastic master transcription factor, for cancer invasion. We show that ABL directly binds to, phosphorylates, and activates RUNX2 through its SH2 domain in a kinase activity-dependent manner and that the complex formation of these proteins is required for expression of its target gene MMP13. Additionally, we show that the RUNX2 transcriptional activity is dependent on the number of its tyrosine residues that are phosphorylated by ABL. In addition to regulation of RUNX2 activity, we show that ABL transcriptionally enhances RUNX2 expression through activation of the bone morphogenetic protein (BMP)-SMAD pathway. Lastly, we show that ABL expression in highly metastatic breast cancer MDA-MB231 cells is associated with their invasive capacity and that ABL-mediated invasion is abolished by depletion of endogenous RUNX2 or MMP13. Our genetic and biochemical evidence obtained in this study contributes to a mechanistic insight linking ABL-mediated phosphorylation and activation of RUNX2 to induction of MMP13, which underlies a fundamental invasive capacity in cancer and is different from the previously described model of transcriptional activation., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 He, Matsumoto, Asano, Yamamura, Katsuyama, La Rose, Tomonobu, Komalasari, Sakaguchi, Rottapel and Wada.)
- Published
- 2021
- Full Text
- View/download PDF
47. Endonuclease increases efficiency of osteoblast isolation from murine calvariae.
- Author
-
Asano Y, Matsumoto Y, La Rose J, He F, Katsuyama T, Ziyi W, Tsuji S, Kamioka H, Rottapel R, and Wada J
- Subjects
- Animals, Cells, Cultured, Mice, Mice, Inbred C57BL, Osteoblasts metabolism, Skull metabolism, Cell Differentiation, Cell Proliferation, Endonucleases metabolism, Osteoblasts cytology, Osteogenesis, Skull cytology
- Abstract
Bone is a highly dynamic organ that undergoes remodeling equally regulated by osteoblast-mediated bone formation and osteoclast-mediated bone resorption. To clarify the regulation of osteoblastogenesis, primary murine osteoblasts are required for an in vitro study. Primary osteoblasts are isolated from neonatal calvariae through digestion with collagenase. However, the number of cells collected from one pup is not sufficient for further in vitro experiments, leading to an increase in the use of euthanized pups. We hypothesized that the viscosity of digested calvariae and digestion solution supplemented with collagenase results in cell clumping and reduction of isolated cells from bones. We simply added Benzonase, a genetically engineered endonuclease that shears all forms of DNAs/RNAs, in order to reduce nucleic acid-mediated viscosity. We found that addition of Benzonase increased the number of collected osteoblasts by three fold compared to that without Benzonase through reduction of viscosity. Additionally, Benzonase has no effect on cellular identity and function. The new osteoblast isolation protocol with Benzonase minimizes the number of neonatal pups required for an in vitro study and expands the concept that isolation of other populations of cells including osteocytes that are difficult to be purified could be modified by Benzonase.
- Published
- 2021
- Full Text
- View/download PDF
48. Gain-of-function variants in SYK cause immune dysregulation and systemic inflammation in humans and mice.
- Author
-
Wang L, Aschenbrenner D, Zeng Z, Cao X, Mayr D, Mehta M, Capitani M, Warner N, Pan J, Wang L, Li Q, Zuo T, Cohen-Kedar S, Lu J, Ardy RC, Mulder DJ, Dissanayake D, Peng K, Huang Z, Li X, Wang Y, Wang X, Li S, Bullers S, Gammage AN, Warnatz K, Schiefer AI, Krivan G, Goda V, Kahr WHA, Lemaire M, Lu CY, Siddiqui I, Surette MG, Kotlarz D, Engelhardt KR, Griffin HR, Rottapel R, Decaluwe H, Laxer RM, Proietti M, Hambleton S, Elcombe S, Guo CH, Grimbacher B, Dotan I, Ng SC, Freeman SA, Snapper SB, Klein C, Boztug K, Huang Y, Li D, Uhlig HH, and Muise AM
- Subjects
- Adult, Animals, Arthritis immunology, Arthritis pathology, Arthritis therapy, Base Sequence, Bone Marrow Transplantation, Colitis immunology, Colitis pathology, Colitis therapy, Dermatitis immunology, Dermatitis pathology, Dermatitis therapy, Family, Female, Gene Expression, Gene Knock-In Techniques, Humans, Infant, Lymphoma, Large B-Cell, Diffuse immunology, Lymphoma, Large B-Cell, Diffuse pathology, Lymphoma, Large B-Cell, Diffuse therapy, Male, Mice, Mice, Knockout, Middle Aged, Mutation, Pedigree, Protein Kinase Inhibitors pharmacology, Syk Kinase antagonists & inhibitors, Syk Kinase deficiency, Arthritis genetics, Colitis genetics, Dermatitis genetics, Lymphoma, Large B-Cell, Diffuse genetics, Syk Kinase genetics
- Abstract
Spleen tyrosine kinase (SYK) is a critical immune signaling molecule and therapeutic target. We identified damaging monoallelic SYK variants in six patients with immune deficiency, multi-organ inflammatory disease such as colitis, arthritis and dermatitis, and diffuse large B cell lymphomas. The SYK variants increased phosphorylation and enhanced downstream signaling, indicating gain of function. A knock-in (SYK-Ser544Tyr) mouse model of a patient variant (p.Ser550Tyr) recapitulated aspects of the human disease that could be partially treated with a SYK inhibitor or transplantation of bone marrow from wild-type mice. Our studies demonstrate that SYK gain-of-function variants result in a potentially treatable form of inflammatory disease.
- Published
- 2021
- Full Text
- View/download PDF
49. Inhibition of relaxin autocrine signaling confers therapeutic vulnerability in ovarian cancer.
- Author
-
Burston HE, Kent OA, Communal L, Udaskin ML, Sun RX, Brown KR, Jung E, Francis KE, La Rose J, Lowitz J, Drapkin R, Mes-Masson AM, and Rottapel R
- Subjects
- Animals, Cell Line, Tumor, Female, Humans, Mice, Ovarian Neoplasms pathology, Ovarian Neoplasms therapy, Autocrine Communication, Carcinogenesis metabolism, MAP Kinase Signaling System, Neoplasm Proteins metabolism, Ovarian Neoplasms metabolism, Relaxin metabolism, Wnt Signaling Pathway
- Abstract
Ovarian cancer (OC) is the most deadly gynecological malignancy, with unmet clinical need for new therapeutic approaches. The relaxin peptide is a pleiotropic hormone with reproductive functions in the ovary. Relaxin induces cell growth in several types of cancer, but the role of relaxin in OC is poorly understood. Here, using cell lines and xenograft models, we demonstrate that relaxin and its associated GPCR RXFP1 form an autocrine signaling loop essential for OC in vivo tumorigenesis, cell proliferation, and viability. We determined that relaxin signaling activates expression of prooncogenic pathways, including RHO, MAPK, Wnt, and Notch. We found that relaxin is detectable in patient-derived OC tumors, ascites, and serum. Further, inflammatory cytokines IL-6 and TNF-α activated transcription of relaxin via recruitment of STAT3 and NF-κB to the proximal promoter, initiating an autocrine feedback loop that potentiated expression. Inhibition of RXFP1 or relaxin increased cisplatin sensitivity of OC cell lines and abrogated in vivo tumor formation. Finally, we demonstrate that a relaxin-neutralizing antibody reduced OC cell viability and sensitized cells to cisplatin. Collectively, these data identify the relaxin/RXFP1 autocrine loop as a therapeutic vulnerability in OC.
- Published
- 2021
- Full Text
- View/download PDF
50. Advances in ovarian cancer, from biology to treatment.
- Author
-
McMullen M, Karakasis K, Rottapel R, and Oza AM
- Subjects
- Biology, Carcinoma, Ovarian Epithelial, Female, Humans, Ovarian Neoplasms diagnosis
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.